Clinical Scorecard: Variations in the Relationship Between Hypnotic Categories and New Cardiovascular Events in Patients with Insomnia

At a Glance

Key Highlights

• Benzodiazepine use is associated with increased risk of cardiovascular events, including heart failure, in insomnia patients.
• Z-drugs do not significantly increase cardiovascular event risk but may slightly increase heart failure risk.
• Cognitive-behavioural therapy is the recommended first-line treatment for insomnia and may reduce cardiovascular risk.

Guideline-Based Recommendations

Diagnosis

• Insomnia diagnosis based on self-reported difficulty falling asleep or nocturnal awakenings.

Management

• First-line treatment is cognitive-behavioural therapy for insomnia.
• Pharmacological treatment with hypnotics (benzodiazepines or Z-drugs) should be considered if CBT is insufficient.
• Long-term use of hypnotics, especially benzodiazepines, should be approached with caution due to adverse effects.

Monitoring & Follow-up

• Monitor cardiovascular outcomes in patients using hypnotics, especially benzodiazepines.
• Assess for adverse effects including psychomotor impairment, respiratory suppression, tolerance, dependence, and withdrawal.

Risks

• Benzodiazepines may increase risk of cardiovascular death, heart failure, and rehospitalization.
• Z-drugs have a minimal but statistically significant increase in heart failure risk.
• Potential confounding factors and lack of dosage/duration data limit definitive causal conclusions.

Patient & Prescribing Data

124,445 insomnia patients aged 40–69 years from the UK Biobank cohort

Propensity score matching and Mendelian randomization analyses indicate heterogeneous cardiovascular risks by hypnotic category; benzodiazepines pose higher risk than Z-drugs.

Clinical Best Practices

• Prioritize cognitive-behavioural therapy as first-line insomnia treatment to reduce cardiovascular risk.
• Use hypnotics judiciously, limiting long-term benzodiazepine use due to cardiovascular and other adverse effects.
• Consider patient sex as females may be more susceptible to cardiovascular risks from benzodiazepines.
• Recognize limitations of current evidence and await interventional studies for clearer guidance.
• Incorporate lifestyle modifications and non-pharmacological therapies as adjuncts to insomnia management.

References

• Hypnotic use and the risk of cardiovascular diseases in insomnia patients, Y. Xie et al.
• European Insomnia Guideline update